Search Results - "SCHOEMAKER, N. E"

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin by SCHOEMAKER, N. E, VAN KESTEREN, C, GRAZIA PORRO, M, BEIJNEN, J. H, SCHELLENS, J. H. M, TEN BOKKEL HUININK, W. W, ROSING, H, JANSEN, S, SWART, M, LIEVERST, J, FRAIER, D, BREDA, M, PELLIZZONI, C, SPINELLI, R

“…Polymeric drug conjugates are a new and experimental class of drug delivery systems with pharmacokinetic promises. The antineoplastic drug camptothecin was…”
Get full text

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer by SCHOEMAKER, N. E, KUPPENS, I. E. L. M, VOZNYI, E, NORUM, J, FENNELLY, D, TVEIT, K. M, GARIN, A, GRUIA, G, MOURIER, A, SIBAUD, D, LEFEBVRE, P, BEIJNEN, J. H, MOISEYENKO, V, SCHELLENS, J. H. M, TEN BOKKEL HUININK, W. W, GLIMELIUS, B, KJAER, M, STARKHAMMER, H, RICHEL, D. J, SMAALAND, R, BERTELSEN, K, POULSEN, J. P

“…The purpose of this phase II trial was to compare the efficacy, safety and pharmacokinetics of four irinotecan schedules for the treatment of metastatic…”
Get full text

Phase I and Pharmacokinetic Study of a Daily Times 5 Short Intravenous Infusion Schedule of 9-Aminocamptothecin in a Colloidal Dispersion Formulation in Patients With Advanced Solid Tumors by HERBEN, V. M. M, VAN GIJN, R, SCHELLENS, J. H. M, SCHOT, M, LIEVERST, J, HILLEBRAND, M. J. X, SCHOEMAKER, N. E, PORRO, M. G, BEIJNEN, J. H, TEN BOKKEL HUININK, W. W

“…To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of 9-aminocamptothecin (9-AC) in a colloidal dispersion…”
Get full text

High-performance liquid chromatographic analysis for the determination of a novel polymer-bound camptothecin derivative (MAG-camptothecin) and free camptothecin in human plasma by Schoemaker, Nadja E, Frigerio, Enrico, Fraier, Daniela, Schellens, Jan H.M, Rosing, Hilde, Jansen, Sindy, Beijnen, Jos H

“…A selective HPLC assay is described for the determination of free and total (free plus polymer-bound) camptothecin (CPT) in human plasma after administration…”
Get full text

Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel–cisplatin–topotecan in a phase I study by Schoemaker, Nadja E, Herben, Virginie MM, de Jong, Laurina A, van Waardenburg, Robert CAM, Pluim, Dick, ten Bokkel Huinink, Wim W, Beijnen, Jos H, Schellens, Jan HM

“…Topotecan stabilizes the topoisomerase I (Topo I) cleavable complex. We measured Topo I levels in white blood cells of patients with ovarian cancer treated…”
Get full text

Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours by SCHOEMAKER, Nadja E, KUPPENS, I. E. L. M, TEN BOKKEL HUININK, Wim W, LEFEBVRE, Patricia, BEIJNEN, Jos H, ASSADOURIAN, Sylvie, SANDERINK, Ger-Jan, SCHELLENS, Jan H. M

“…A phase I study was conducted with oral irinotecan given daily for 14 days every 3 weeks in 45 patients with solid tumours to establish the maximum tolerated…”
Get full text

Phase I, pharmacokinetic, and pharmacodynamic study of carboplatin and topotecan administered in two different schedules by Boss, D. S., Siegel-Lakhai, W. S., Schoemaker-van Egmond, N. E., Pluim, D., Rosing, H., Ten Bokkel-Huinink, W. W., Beijnen, J. H., Schellens, J. H.

“…Abstract only 2561 Background: Preclinical studies showed sequence dependent synergy of the combination of topoisomerase I inhibitors and platinum agents. This…”
Get full text

High-performance liquid chromatographic analysis of the anticancer drug irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by SCHOEMAKER, Nadja E, ROSING, Hilde, JANSEN, Sindy, SCHELLENS, Jan H. M, BEIJNEN, Jos H

“…A rapid, sensitive, and specific high-performance liquid chromatography (HPLC) method for the simultaneous determination of irinotecan (CPT-11) and its active…”
Get full text

Randomized Phase I Clinical and Pharmacologic Study of Weekly versus Twice-Weekly Dose-intensive Cisplatin and Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer by CRUL, Mirjam, SCHOEMAKER, Nadja E, SCHELLENS, Jan H. M, PLUIM, Dick, MALIEPAARD, Marc, UNDERBERG, René W. M, SCHOT, Margaret, SPARIDANS, Rolf W, BAAS, Paul, BEIJNEN, Jos H, VAN ZANDWIJK, Nico

“…Purpose: To establish the maximum dose intensity of cisplatin plus gemcitabine on a weekly or two-weekly schedule in patients with advanced non-small cell lung…”
Get full text

Urinary and fecal excretion of topotecan in patients with malignant solid tumours by HERBEN, Virginie M. M, SCHOEMAKER, Nadja E, ROSING, Hilde, VAN ZOMEREN, Desiree M, TEN BOKKEL HUININK, Wim W, DUBBELMAN, Ria, HEARN, Solange, SCHELLENS, Jan H. M, BEIJNEN, Jos H

“…The objectives of the study were to determine the pharmacokinetics and routes of excretion of topotecan following intravenous or oral administration to…”
Get full text

Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule by SCHOEMAKER, Nadja E, MATHOT, Ron A. A, SCHÖFFSKI, Patrick, ROSING, Hilde, SCHELLENS, Jan H. M, BEIJNEN, Jos H

“…Our aim was to develop an optimal sampling strategy for the description of the pharmacokinetics of rubitecan and its active metabolite 9-aminocamptothecin…”
Get full text